Abstract:Objective To determine the morbidity of cervical intraepithelial neoplasia 2+(CIN2+) and CIN3+of different human papillomavirus(HPV)subtype infection combined with different cytology status.Methods The Shenzhen Cervical Cancer Screening Trial Ⅰ & Ⅱ(SHENCCASTⅠ&Ⅱ)are population-based cross-sectional cervical cancer screening studis conducted in Shenzhen and surrounding area from 2008 to2010.A total of 12 097 women who aged 25-59 years were included in the analysis.All of these women were detected by liquid-based cytology test and several high-risk HPV-DNA tests.The ones with HPV positive or atypical squamous cells of undetermined sign(ASC-US)were sequentially conducted by cervical biopsy vaginoscopy.Finally,10 805 samples with complete data of hybrid capture 2(HC2),the polymerase chain reaction-based matrix-assisted laser desorption/ionization time-of-flight assay(MALDI-TOF), HPV genotyping detection,cytology and pathology results were analyzed.Results The top 6 infection rates of HR-HPV in CIN2+and CIN3+were HPV16, HPV52, HPV58, HPV33, HPV31, HPV18.The highest constituent ratio of cytology in CIN 2+and CIN3+was high grade squamous intraepithelial lesion(HSIL).The morbidities of CIN2+of patients infected with HPV16, HPV31, HPV58, HPV33, HPV18, HPV52 were 41.3%, 31.5%, 30.6%, 28.7%, 28.2%, 17.7 %, respectively, while the morbidities of CIN3+of those were 33.5 %,20.5%, 19.4%, 15.7%, 19.2%,8.3%, respectively.The morbidities of CIN2+in negative intraepithelial lesion or malignancy(NILM),ASC-US, low grade squamous intraepithelial lesion(LSIL), atypical squamous cell cannot exclude high-grade squamous intraepithelial lesion(ASC-H), high grade squamous intraepithelial lesion(HSIL), atypical glandular cell(AGC)samples were 0.4%, 6.9%, 11.1%,36.4%,82.0%,16.7%,respectively,while the morbidities of CIN3+of those were 0.2%,3.1%, 4.2%,22.7%, 64.8%, 0.0%, respectively.The morbidities of CIN2+in NILM combined with HPV16, HPV18,HPV31, HPV33 infection were 12.6%, 13.3%, 15.8% and 11.5%, respectively, while the morbidities of CIN3+of those were 10.3%,11.1%,7.9%and 7.7%,respectively.The morbidities of CIN2+and CIN3+in ASC-US combining with hrHPV infection were high, and the top 6 subtypes associated with high risk of CIN2+were HPV31(35.7%), HPV33(26.9%), HPV16(26.5%), HPV58(22.4%), HPV52(18.6%), HPV68(15.4%), while those associated with high risk of CIN 3+were HPV16 (20.4%),HPV31(14.3%),HPV33(11.5%), HPV58(8.6%), HPV68(7.7%), HPV52(5.8%). Conclusions Cytology combined with HPV genotyping detection can more effectively estimate the morbidity risks of CIN2+and CIN3+.Both high prevalence rates and high risks associated with CIN 2+and CIN3+of HPV31,HPV33,HPV52 and HPV58 are observed.NILM and ASC-US status combined with these subtypes mentioned above are advised to be conducted by colposcopy.

High-risk HPV genotyping for cervical intraepithelial neoplasia grade 2 or worse:A comparison of single types and type combinations

Clinical Significance of Genotyping for Human Papillomavirus (HPV) 16 18/45 Combined with Cytology in Cervical Exfoliated Cells in HPV Oncogenic Mrna-Positive Women

Extended Human Papilloma Virus Genotyping for Risk Assessment of Cervical Intraepithelial Neoplasia Grade 2 or Worse in a Cohort Study

Extended HPV Genotyping for Risk Assessment of Cervical Intraepithelial Neoplasia Grade 2/3 or Worse in a Cohort Study

Diagnostic accuracy of extended HPV DNA genotyping and its application for risk-based cervical cancer screening strategy

Evaluation of CIN2+/CIN3+risk of Different HPV Subtypes Infection Combined with Abnormal Cytology Status

Extended Human Papillomavirus Genotype Distribution and Cervical Cytology Results in a Large Cohort of Chinese Women with Invasive Cervical Cancers and High-Grade Squamous Intraepithelial Lesions.

Detection of human papillomavirus genotypes in cervical carcinoma and intraepithelial neoplasia.

Diagnostic value of high-risk HPV other than type 16/18 in high-grade cervical neoplasia among cytology-negative women: A multicenter retrospective study

High-Risk Genotypes of Human Papillomavirus at Diverse Anogenital Sites among Chinese Women: Infection Features and Potential Correlation with Cervical Intraepithelial Neoplasia

Human Papillomavirus Genotyping to Predict the Risk of Cervical Precancerous Lesions or Cancer in Women with Minor Abnormal Cytology in China.

Risk analysis of CIN2, 3 in the HR-HPV subtypes infected women with normal cervical cytology results

The role of high-risk HPV genotyping in the detection of high-grade intraepithelial neoplasia or cancer in women with negative cytology but positivity for HPV: A hospital-based investigation in northeastern China

HPV genotyping of cervical histologic specimens of 61, 422 patients from the largest women hospital in China

Performance of High-Risk Human Papillomavirus Testing in the Triage of Abnormal Cervical Cytology among Chinese Younger Women in Shanghai, China

Prevalence Characteristics of High-Risk Human Papillomaviruses in Women Living in Shanghai with Cervical Precancerous Lesions and Cancer

Clinical efficacy of human papillomavirus (HPV) genotyping in screening for cervical disorders

Relationship between High-risk HPV Infection and Cervical Lsesions in Cervical Cancer Opportunistic Screening

Clinical Performance of APTIMA Human Papillomavirus (HPV) 16 18/45 Mrna Genotyping Testing for the Detection of Cervical Intraepithelial Neoplasia 3 (CIN3) or Cancer in a Select Group of Chinese Women

Type-specific Distribution of Cervical hrHPV Infection and the Association with Cytological and Histological Results in a Large Population-based Cervical Cancer Screening Program: Baseline and 3-year Longitudinal Data

[Risk stratification of type-specific human papillomavirus for cervical precancers: evidence from a cross-sectional study in Shenzhen]